# US 2010/0074929 A1 · Administration of agents mimicking dopachrome tautomerase (trp-2) activity for protecting hair follicle melanocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074929 A1
- Document ID: US20100074929A1
- Status: Published application
- Kind: A1
- Application number: 12/541,398
- Filed: 2009-08-14
- Published: 2010-03-25
- Earliest claimed: 2002-06-11
- Assignees: L'oreal
- Inventors: Stephane Commo; Olivier Gaillard; Bruno Bernard
- Web page: https://patentgrep.com/patent/US20100074929A1

## CPC

- C12Q 1/533: involving isomerase
- A61K 8/19: containing inorganic ingredients
- A61Q 5/00: Preparations for care of the hair
- A61Q 5/02: Preparations for cleaning the hair
- A61Q 5/06: Preparations for styling the hair, e.g. by temporary shaping or colouring
- A61Q 5/10: Preparations for permanently dyeing the hair
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Agents mimicking DOPAchrome tautomerase activity are administered, notably topically applied, to protect and/or regenerate the melanocytes of hair follicles, to promote the cyclic renewal of the follicular pigmentation unit, to prevent and/or limit and/or arrest the development of canities, and to maintain the natural pigmentation of gray or white head hair and/or body hair.

## Claims

### Claim 1

A regime or regimen for protecting the melanocytes of hair follicles, comprising administering to an individual in need of such treatment, for such period of time as required to elicit the desired effect, a thus effective amount of at least one active agent mimicking DOPAchrome tautomerase activity.

### Claim 2

A regime or regimen for combating the disappearance of the melanocytes of hair follicles by maintaining and/or by regenerating the population of active melanocytes of the bulbs and of the quiescent melanocytes of the upper region of hair follicles, comprising administering to an individual in need of such treatment, for such period of time as required to elicit the desired effect, a thus effective amount of at least one active agent mimicking DOPAchrome tautomerase activity.

### Claim 3

A regime or regimen for promoting the cyclic renewal of the follicular pigmentation unit, comprising administering to an individual in need of such treatment, for such period of time as required to elicit the desired effect, a thus effective amount of at least one active agent mimicking DOPAchrome tautomerase activity.

### Claim 4

(canceled)

### Claim 5

A regimen or regimen for maintaining the natural pigmentation of gray or white head hair and/or body hair, comprising administering to an individual in need of such treatment, for such period of time as required to elicit the desired effect, a thus effective amount of at least one active agent mimicking DOPAchrome tautomerase activity.

### Claim 6 (depends on 1)

The regime or regimen as defined by claim 1, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of synthetic molecules mimicking SOD, 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, propyl gallate, quercetin, trolox, histidine, tryptophan, methionine, metal chelators, 21-aminosteroids, the salen-manganese complex, EUK-8, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, ebselen, non-antioxidant compounds, MIF and analogs thereof.

### Claim 7

A cosmetic composition useful for combating canities, comprising a thus effective amount of at least one active agent mimicking DOPAchrome tautomerase activity selected from the group consisting of synthetic molecules mimicking SOD, 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, propyl gallate, quercetin, trolox, histidine, tryptophan, methionine, metal chelators, 21-aminosteroids, the salen-manganese complex, EUK-8, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, ebselen, non-antioxidant compounds, MIF and analogs thereof, formulated into a cosmetically acceptable medium therefor.

### Claim 8 (depends on 7)

The cosmetic composition as defined by claim 7, further comprising at least one other active agent or plant extract for combating desquamative states of the scalp, for promoting hair regrowth and/or for eliciting propigmenting activity.

### Claim 9 (depends on 7)

The cosmetic composition as defined by claim 7, said at least one active agent mimicking DOPAchrome tautomerase activity comprising from 0.001 to 10% by weight per volume thereof.

### Claim 10 (depends on 7)

The cosmetic composition as defined by claim 7, said at least one active agent mimicking DOPAchrome tautomerase activity comprising from 0.01 to 5% by weight per volume thereof.

### Claim 11 (depends on 7)

The cosmetic composition as defined by claim 7, said at least one active agent mimicking DOPAchrome tautomerase activity comprising from 0.1 to 1% by weight per volume thereof.

### Claim 12 (depends on 7)

The cosmetic composition as defined by claim 7, formulated for topical application.

### Claim 13 (depends on 7)

The cosmetic composition as defined by claim 7, formulated for oral administration.

### Claim 14 (depends on 12)

The cosmetic composition as defined by claim 12, comprising a hair styling cream or gel, a hair lotion, a restructuring lotion, a dye composition, a shampoo, or a conditioner.

### Claim 15 (depends on 7)

The cosmetic composition as defined by claim 7, said at least one active agent mimicking DOPAchrome tautomerase activity being encapsulated in a coating.

### Claim 16 (depends on 15)

The cosmetic composition as defined by claim 15, said at least one active agent mimicking DOPAchrome tautomerase activity being encapsulated in microspheres, nanospheres, oleosomes or nanocapsules.

### Claim 17 (depends on 15)

The cosmetic composition as defined by claim 15, the coating in which said at least one active agent mimicking DOPAchrome tautomerase activity is encapsulated having a diameter of less than or equal to 10 μm.

### Claim 18

A method for identifying an agent mimicking DOPAchrome tautomerase activity, comprising the following steps:
a—culturing a population of melanocytes;
b—separating into two populations the population of melanocytes obtained at the end of step (a), designated Mel-A and Mel-B respectively, culturing Mel-A in a medium A where the melanocytes express little or no DOPAchrome tautomerase and Mel-B in a medium B containing at least one factor promoting the expression of DOPAchrome tautomerase;
c—exposing the Mel-A population to a condition inducing apoptosis or senescence in culture in the presence (Mel-A(+) population) or in the absence (Mel-A(−) population) of a compound for which it is desired to test the DOPAchrome tautomerase mimicking activity;
d—exposing the Mel-B population to a condition inducing apoptosis or senescence in culture identical to the condition selected in step (c) in the absence of the compound for which it is desired to test the DOPAchrome tautomerase activity;
e—comparing the apoptotic or senescent responses of the Mel-A(+) population with Mel-A(−) and of Mel-A(+) with Mel-B;
f—selecting the compounds for which the response is such that the cytotoxicity observed in the Mel-A(+) trial is lower than that observed in the Mel-A(−) trial, and the cytotoxicity observed in the Mel-A(+) trial is close to that observed in the Mel-B trial.

### Claim 19 (depends on 18)

A method for evaluating the cytoprotective activity of an agent mimicking DOPAchrome tautomerase activity capable of being identified by the method as defined by claim 18, comprising the following steps:
a—culturing a population of melanocytes in a medium limiting the expression of TRP-2 to a low basal expression;
b—adding a compound mimicking DOPAchrome tautomerase activity to the culture medium;
c—exposing the cells to a condition inducing apoptosis or senescence;
d—measuring the cytotoxicity;
e—selecting the compounds mimicking DOPAchrome tautomerase activity with a cytoprotective effect.

### Claim 20 (depends on 19)

The method as defined by claim 19, step (c) comprising treating the cells with cisplatin.

### Claim 21 (depends on 2)

The regime or regimen as defined by claim 2, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of synthetic molecules mimicking SOD, 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, propyl gallate, quercetin, trolox, histidine, tryptophan, methionine, metal chelators, 21-aminosteroids, the salen-manganese complex, EUK-8, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, ebselen, non-antioxidant compounds, MIF and analogs thereof.

### Claim 22 (depends on 3)

The regime or regimen as defined by claim 3, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of synthetic molecules mimicking SOD, 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, propyl gallate, quercetin, trolox, histidine, tryptophan, methionine, metal chelators, 21-aminosteroids, the salen-manganese complex, EUK-8, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, ebselen, non-antioxidant compounds, MIF and analogs thereof.

### Claim 23 (depends on 5)

The regime or regimen as defined by claim 5, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of synthetic molecules mimicking SOD, 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, propyl gallate, quercetin, trolox, histidine, tryptophan, methionine, metal chelators, 21-aminosteroids, the salen-manganese complex, EUK-8, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, ebselen, non-antioxidant compounds, MIF and analogs thereof.

### Claim 24 (depends on 18)

The method as defined by claim 18, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of synthetic molecules mimicking SOD, 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, propyl gallate, quercetin, trolox, histidine, tryptophan, methionine, metal chelators, 21-aminosteroids, the salen-manganese complex, EUK-8, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, ebselen, non-antioxidant compounds, MIF and analogs thereof.

### Claim 25 (depends on 6)

The regime or regimen as defined by claim 6, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, trolox, histidine, tryptophan, metal chelators, 21-aminosteroids, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, and ebselen.

### Claim 26 (depends on 7)

The cosmetic composition as defined by claim 7, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, trolox, histidine, tryptophan, metal chelators, 21-aminosteroids, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, and ebselen.

### Claim 27 (depends on 21)

The regime or regimen as defined by claim 21, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, trolox, histidine, tryptophan, metal chelators, 21-aminosteroids, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, and ebselen.

### Claim 28 (depends on 22)

The regime or regimen as defined by claim 22, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, trolox, histidine, tryptophan, metal chelators, 21-aminosteroids, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, and ebselen.

### Claim 29 (depends on 23)

The regime or regimen as defined by claim 23, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, trolox, histidine, tryptophan, metal chelators, 21-aminosteroids, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, and ebselen.

### Claim 30 (depends on 24)

The method as defined by claim 24, said at least one active agent mimicking DOPAchrome tautomerase activity being selected from the group consisting of 5,6,7,8-tetrahydro-1-naphthaneol compounds, oxygenated benzoheterocycle compounds, cyclodextrin compounds, silicon-containing compounds derived from ascorbic acid, lysine or arginine pyrrolidonecarboxylate, tert-butyl benzylidenecamphor compounds, benzylidenecyclanone compounds, modified diorganopolysiloxanes, lipophilic compounds of benzylidenecamphor, hydrophilic compounds of benzylidenecamphor, benzylcyclanone compounds, antioxidant polymers, combinations of mono- and diesters of cinnamic acid and of vitamin C, polyamines, putrescine, spermidine, spermine, Di-amines, Tri-amines, Tetra-amines, trolox, histidine, tryptophan, metal chelators, 21-aminosteroids, α-phenyl-tert-butyl nitrol (PBN) and compounds thereof, and ebselen.
